EUVIMEDEuropean Health Evidence
Uhr 7/7Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial

Yuan Tang, Hai-Tao Zhou, Tong-Zhen Xu, Ning Li, Li-Ming Jiang, Jun Jiang, Ning-Ning Lu, Shuai Li, Si-Lin Chen, Hui-Ying Ma, Yong Cai, Yong-Heng Li, Yuan Zhu, Ming-Yuan He, Xin Wang, Ke Liu, Hong-Yan Zhang, Jun Wang, Ting Zhao, Gao-Feng Li, Jia-Lin Yang, Kuan Zhang, Wen-Ling Wang, Wei-Wei Xiao, Yihebali Chi, Lin Yang, Ai-Ping Zhou, Shuang-Mei Zou, Hui Fang, Shu-Lian Wang, Hai-Zeng Zhang, Xi-Shan Wang, Li-Chun Wei, Shi-Xin Liu, Yuan-Hong Gao, Ye-Xiong Li, Chen Hu, Jing Jin

Journal of Clinical Oncology · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

This updated analysis of the STELLAR trial reports 5-year outcomes comparing short-course radiotherapy followed by chemotherapy (SCRT-based total neoadjuvant therapy [TNT]) with standard long-course chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (LARC). Patients with distal or middle-third LARC were randomly assigned to receive either SCRT-based TNT or CRT. At a median follow-up of 68.7 months, the 5-year disease-free survival (DFS) was 62.0% in the TNT group and 58.7% in the CRT group, with a hazard ratio (HR) for DFS of 0.849 (95% CI, 0.662 to 1.089). Five-year overall survival (OS) was significantly higher with TNT (78.1% v 69.7%; HR, 0.739 [95% CI, 0.550 to 0.993]). Distant metastasis (DM) and locoregional recurrence (LRR) rates were similar between the two groups. In high-risk patients (per European Society for Medical Oncology criteria), TNT was associated with improved OS (HR, 0.663 [95% CI, 0.469 to 0.937]) and showed a nonsignificant trend toward improved DFS (HR, 0.765 [95% CI, 0.568 to 1.032]). In patients with DM or LRR, TNT was associated with both improved postrecurrence progression-free survival (HR, 0.691 [95% CI, 0.497 to 0.961]) and postrecurrence survival (HR, 0.698 [95% CI, 0.490 to 0.994]). These results suggest that SCRT-based TNT provides a durable survival advantage and is a viable alternative to CRT, especially in patients with high-risk disease.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Yuan Tang, Hai-Tao Zhou, Tong-Zhen Xu, Ning Li, Li-Ming Jiang, Jun Jiang, Ning-Ning Lu, Shuai Li, Si-Lin Chen, Hui-Ying Ma, Yong Cai, Yong-Heng Li, Yuan Zhu, Ming-Yuan He, Xin Wang, Ke Liu, Hong-Yan Zhang, Jun Wang, Ting Zhao, Gao-Feng Li, Jia-Lin Yang, Kuan Zhang, Wen-Ling Wang, Wei-Wei Xiao, Yihebali Chi, Lin Yang, Ai-Ping Zhou, Shuang-Mei Zou, Hui Fang, Shu-Lian Wang, Hai-Zeng Zhang, Xi-Shan Wang, Li-Chun Wei, Shi-Xin Liu, Yuan-Hong Gao, Ye-Xiong Li, Chen Hu, Jing Jin
Quelle
Journal of Clinical Oncology
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
0732-183X, 1527-7755
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Yuan Tang, Hai-Tao Zhou, Tong-Zhen Xu, Ning Li, Li-Ming Jiang, Jun Jiang, Ning-Ning Lu, Shuai Li, Si-Lin Chen, Hui-Ying Ma, Yong Cai, Yong-Heng Li, Yuan Zhu, Ming-Yuan He, Xin Wang, Ke Liu, Hong-Yan Zhang, Jun Wang, Ting Zhao, Gao-Feng Li, Jia-Lin Yang, Kuan Zhang, Wen-Ling Wang, Wei-Wei Xiao, Yihebali Chi, Lin Yang, Ai-Ping Zhou, Shuang-Mei Zou, Hui Fang, Shu-Lian Wang, Hai-Zeng Zhang, Xi-Shan Wang, Li-Chun Wei, Shi-Xin Liu, Yuan-Hong Gao, Ye-Xiong Li, Chen Hu, Jing Jin (2026). Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02387
RIS BibTeX CSL-JSON